Study Melanoma with Peptide Innovations & New Literature
Published on 11/08/2022
The potential immunogenicity of mutation-derived neo-antigens makes them strong candidates for personalized cancer therapy approaches. Melanoma is associated with a high somatic mutation frequency leading to an increased likelihood of neo-antigen formation.
Besides the need for therapy, this cancer is also a suitable model for neo-epitope prediction and verification. Vaccine and cell therapy development [6,7] as well as the implementation of appropriate humoral and cellular immune monitoring strategies are often pioneered in melanoma research.
Therefore, we developed a large variety of readily available peptide-based tools and services supporting all development phases of Melanoma-related Immunotherapies.
- common melanoma- associated antigens, e.g. MAGE, PRAME or NY-ESO, with new products continuously added to the catalog
- for T-cell immunity profiling & epitope discovery
- immunodominant epitopes representing melanoma-associated antigens
- for stimulation of antigen-specific T cells in T cell assays
- custom peptides produced under stringent quality regulations
- for development of novel vaccines & cell therapies and clinical immune monitoring
- high density or multiwell peptides microarrays
- for epitope resolved humoral immune response profiling and antibody epitope mapping
The following list of publications exemplifies the range of our products, and their applicability in recent cancer immunotherapy research:
- Lanscape of Helper and Regulatory Antitumour CD4+ T cells in Melanoma
Oliveira et al., Nature (2022) – PMID: 35508657 - Local Delivery of low-dose anti–CTLA-4 to the Melanoma Lymphatic Basin leads to systemic T reg Reduction and Effector T cell Activation
Van Pul et al., Science Immunology (2022) – PMID: 35857579 - Functional T Cell Reactivity to Melanocyte Antigens is lost during the Progression of Malignant Melanoma, but Is restored by Immunization
Przybyla et al., Cancers (Basel) (2021) – PMID: 33435427 - Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
Stanojevic et al., Cytotherapy (2021) – PMID: 33832817 - Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
Akache et al., Pharmaceutics (2021) – PMID: 33673382 - Neoantigens in Cancer Immunotherapy – Review
Schumacher & Schreiber, Science (2015) – PMID: 25838375 - An immunogenic personal Neoantigen Vaccine for Patients with Melanoma – Letter
Ott et al., Nature (2017) – PMID: 28678778
Find more references.
If you have any questions or want to discuss our large varity of custom peptide synthesis formats, pease contact us.